Next Article in Journal
Systematic Review of Utility Values Used in the Pharmacoeconomic Evaluations for Schizophrenia: Implications on Cost-Effectiveness Results
Previous Article in Journal
Has OMP Legislation Been Successful? Yes, Though the Orphan Drug Market Remains Immature
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JMAHP
Volume 7
Issue 1
10.1080/20016689.2019.1648971
jmahp-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Comparison of Health Technology Assessment for New Medicines in France and England: An Example Based on Ixazomib for Patients with Relapsed or Refractory Multiple Myeloma

by
Xavier Armoiry
1,2,*,
Hans-Martin Spath
3,
Aileen Clarke
2,
Martin Connock
2,
Paul Sutcliffe
2 and
Claude Dussart
3
1
Pharmacy Department, University of Lyon, School of Pharmacy (ISPB)/UMR CNRS 5510 MATEIS/Lyon University Hospitals, “Edouard Herriot” Hospital, Lyon, France
2
Warwick Medical School, University of Warwick, Coventry, UK
3
University Claude Bernard Lyon 1, University of Lyon, EA 4129 P2S (Parcours, Santé, Systémique), Lyon, France
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2019, 7(1), 1648971; https://doi.org/10.1080/20016689.2019.1648971
Submission received: 26 February 2019 / Revised: 12 July 2019 / Accepted: 22 July 2019 / Published: 30 July 2019

Abstract

Introduction: The appraisal of medicines is often a complex and iterative process. We compared the health technology assessment (HTA) process in England and France taking as a case study the example of ixazomib for multiple myeloma. Methods: We undertook an analysis of eight relevant published documents identifed from the websites of the French and English HTA bodies (HAS and NICE, respectively). We analyse patients’ availability of ixazomib resulting in the different stages of the appraisal process. Results: We identified differences in the assessment, one of these being the use of an appraisal scope in England allowing the differentiation of populations and comparators according to previously approved treatments. Ixazomib became available earlier in France as part of an early access programme, but the availability was soon discontinued for newly eligible patients following an HAS determination that Ixazomib yielded no additional benefit. This opinion resulted in long pricing discussions. In England, despite the absence of an early access programme and following a process that included cost-effectiveness evaluation combined with pricing discussions, the medicine was fairly rapidly recommended for use. Conclusions: Differences in the HTA process may result in appreciable differences in time from marketing authorisation to health service adoption of newly licensed drugs.
Keywords: NICE; HAS; health technology assessment; France; England; Ixazomib; multiple myeloma NICE; HAS; health technology assessment; France; England; Ixazomib; multiple myeloma

Share and Cite

MDPI and ACS Style

Armoiry, X.; Spath, H.-M.; Clarke, A.; Connock, M.; Sutcliffe, P.; Dussart, C. Comparison of Health Technology Assessment for New Medicines in France and England: An Example Based on Ixazomib for Patients with Relapsed or Refractory Multiple Myeloma. J. Mark. Access Health Policy 2019, 7, 1648971. https://doi.org/10.1080/20016689.2019.1648971

AMA Style

Armoiry X, Spath H-M, Clarke A, Connock M, Sutcliffe P, Dussart C. Comparison of Health Technology Assessment for New Medicines in France and England: An Example Based on Ixazomib for Patients with Relapsed or Refractory Multiple Myeloma. Journal of Market Access & Health Policy. 2019; 7(1):1648971. https://doi.org/10.1080/20016689.2019.1648971

Chicago/Turabian Style

Armoiry, Xavier, Hans-Martin Spath, Aileen Clarke, Martin Connock, Paul Sutcliffe, and Claude Dussart. 2019. "Comparison of Health Technology Assessment for New Medicines in France and England: An Example Based on Ixazomib for Patients with Relapsed or Refractory Multiple Myeloma" Journal of Market Access & Health Policy 7, no. 1: 1648971. https://doi.org/10.1080/20016689.2019.1648971

APA Style

Armoiry, X., Spath, H. -M., Clarke, A., Connock, M., Sutcliffe, P., & Dussart, C. (2019). Comparison of Health Technology Assessment for New Medicines in France and England: An Example Based on Ixazomib for Patients with Relapsed or Refractory Multiple Myeloma. Journal of Market Access & Health Policy, 7(1), 1648971. https://doi.org/10.1080/20016689.2019.1648971

Article Metrics

Back to TopTop